Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.120 estudios en Neurología (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. A Study Using Targeted Inhibitors to Treat Specific Tumor Mutations in Patients with Meningiomas Rochester, Minn., Jacksonville, Fla. This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. A Study to Investigate Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to identify mechanisms and predictors for the persistence of post-traumatic headache and methods to treat post-traumatic headache and prevent its persistence. A Study to Investigate Biomarkers for Phenotyping of Neurodegenerative Disorders Jacksonville, Fla. The primary purpose of this study is to create a Mayo Clinic repository for neurodegenerative disorders such as Parkinson’s disease (PD), Parkinson’s disease dementia and dementia with Lewy bodies (PDD/DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), cortico-basal degeneration (CBD), and other even rarer forms of neurodegeneration. A Study of Lutetium Lu 177 Dotatate (Lutathera®) in Patients with Inoperable, Progressive Meningioma after External Beam Radiation Therapy Rochester, Minn. The purpose of this study is to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 1 meningioma as measured by 6-month PFS rate, and to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 2 or 3 meningioma as measured by 6-month PFS rate. A Study to Develop a Biorepository of Blood Samples from Cancer Patients Participating in the Gemini (IRB 19-006717) Protocol Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to develop a biorepository of blood samples from cancer patients participating in the Gemini (IRB 19-006717) protocol. These samples will be used for future biomarker discovery and other translational studies. A Study of Demyelinating Lesions as a Cause of Progressive Motor Deterioration Rochester, Minn. The purpose of this study is a comprehensive review of the clinical and radiologic history in these patients as well as review of neuropathology in deceased patients, where available. The goal of this research is to investigate the hypothesis that this presentation represents a spatially limited form of CNS inflammatory demyelinating disease. Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery (DISCOVERY) Rochester, Minn. The purpose o fthis study A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset. All participants will undergo baseline screening for evidence of pre-stroke dementia. Those who pass baseline screening will complete a blood draw and a series of cognitive and functional assessments at baseline. Participants will undergo in-person (3-6 months, 18 months) and telephone (annual) follow-up visits for the duration of the study to assess for longitudinal cognitive and functional outcomes. In addition to Tier 1 procedures, at each in-person follow-up visit: Tier 2 participants will also undergo MRI scanning, comprehensive cognitive assessment batteries and longitudinal blood collection; and Tier 3 participants will also complete amyloid- and tau-PET/CT scans. A Study to Evaluate MR of CSF Dynamics Rochester, Minn. The purpose of this study is to evaluate changes in CSF dynamics (e.g., velocity, flow rate) between patients with normal pressure hydrocephalus and healthy controls, as well as patients with other dementia disorders. Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study Rochester, Minn., Mankato, Minn., La Crosse, Wis., Jacksonville, Fla., Eau Claire, Wis., Scottsdale/Phoenix, Ariz., Albert Lea, Minn. The purpose of this study is to demonstrate non-inferior 12-month overall survival of patients with GlioblastomA (GBM) treated with dose escalated hypofractionated radiotherapy compared to standard of care. Also, to demonstrate the safety and favorable quality of life via physician-reported G3+ toxicitycompare if SBRT is non-inferior to standard of care on the proportion of overall survival of patients with glioblastoma 12 months after randomization. A Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging Agent, 18F-OP-801 (18F Hydroxyl Dendrimer) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Healthy Volunteers (HV) Jacksonville, Fla. The purpose of this study is to evaluate the safety, pharmacokinetics and biodistribution of an imaging agent, 18F-OP-801 (18F Hydroxyl Dendrimer), after intravenous administration to patients with Amyotrophic Lateral Sclerosis (ALS) and Healthy Volunteers (HV) Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 99 Ir a página 1010 Ir a página 1111 Ir a página 1212 SiguientePróxima página Solicite una consulta Conocimientos y categoríasInvestigación June 19, 2024 Comparte en: FacebookTwitter U.S. News & World Report reconoce a Mayo Clinic de Rochester (Minnesota), Mayo Clinic de Phoenix y Scottsdale (Arizona) y Mayo Clinic de Jacksonville (Florida) entre los mejores hospitales del país para neurología y neurocirugía en el período 2024-2025. Obtén más información sobre este gran honor NeurologíaPágina inicialdel departamentoSeccionesDescripción generalAnálisis y procedimientosEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicite una ConsultaDescripción generalAnálisis y procedimientosEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones ORG-20117054 Centros y departamentos médicos Neurología